BeiGene, Ltd. (BGNE Quick QuoteBGNE - Free Report) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 20.9% in the past one-month time frame.

The upmove came after the company announced the pricing of its follow-on public offering of American Depositary Shares ("ADS") at $101 per ADS. The gross proceeds from the offering is expected to be roughly $750 million.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

BeiGene currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider Exelixis, Inc. (EXEL Quick QuoteEXEL - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is BGNE going up? Or down? Predict to see what others think:Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>